New Peptide-Based Immunotherapy for Advanced Solid Tumors
Part of Cancer clinical trials.
This early-stage trial tests a new drug that combines a peptide with genetic material (siRNA) designed to help your immune system fight advanced cancers that haven't responded to standard treatments. Researchers want to see if it's safe and whether it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor (like sarcoma, head/neck cancer, or melanoma) that has progressed despite at least two prior treatments and has no other standard options available
- You're between 18 and 70 years old
- Your overall health is good enough to complete the trial (ECOG score 0–1, meaning you can do most daily activities)
- You've waited at least 28 days since your last chemotherapy, radiation, or surgery (or 6 weeks if you received certain specific chemotherapy drugs)
- Your blood counts, liver, and kidney function are within acceptable ranges, and your heart is pumping normally (ejection fraction ≥50%)
- You're not pregnant, don't have active infections (including tuberculosis, HIV, or hepatitis), and don't have uncontrolled heart disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
This early-stage trial tests a new medicine called NCP-IL-22BP mRNA, given as an injection, to see if it is safe and well-tolerated in patients with advanced cancers that have not responded to standard treatments. The medicine is designed to boost your immune system to fight cancer cells.
This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.